U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006571) titled 'At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis' on May 27.
Brief Summary: Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes gradual muscle weakness and loss of muscle mass. It affects all muscles that control movement, speech, swallowing, and breathing. Unfortunately, ALS is currently incurable, and treatments are limited. Only two medications, riluzole and edaravone, have been approved and can slightly extend survival, typically between 20 and 48 months from diagnosis.
Recent research has identified a useful biomarker known as neurofilament light chain (NfL), which i...